Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup
- PMID: 28079598
- DOI: 10.1097/PAS.0000000000000764
Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup
Abstract
The Cancer Genome Atlas recently identified a genomic-based molecular classification of endometrial carcinomas, with 4 molecular categories: (1) ultramutated (polymerase epsilon [POLE] mutated), (2) hypermutated (microsatellite instability), (3) copy number abnormalities-low, and (4) copy number abnormalities-high. Two studies have since proposed models to classify endometrial carcinomas into 4 molecular subgroups, modeled after The Cancer Genome Atlas, using simplified and more clinically applicable surrogate methodologies. In our study, 151 endometrial carcinomas were molecularly categorized using sequencing for the exonuclease domain mutations (EDM) of POLE, and immunohistochemistry for p53 and mismatch repair (MMR) proteins. This separated cases into 1 of 4 groups: (1) POLE EDM, (2) MMR-D, (3) p53 wildtype (p53 wt), or (4) p53 abnormal (p53 abn). Seven gynecologic pathologists were asked to assign each case to one of the following categories: grade 1 to 2 endometrioid carcinoma (EC), grade 3 EC, mucinous, serous carcinoma (SC), clear cell, dedifferentiated, carcinosarcoma, mixed, and other. Consensus diagnosis among all 7 pathologists was highest in the p53 wt group (37/41, 90%), lowest in the p53 abn group (14/36, 39%), and intermediate in the POLE EDM (22/34, 65%) and MMR-D groups (23/40, 58%). Although the majority of p53 wt endometrial carcinomas are grade 1 to 2 EC (sensitivity: 90%), fewer than half of grade 1 to 2 EC fell into the p53 wt category (positive predictive value: 42%). Pure SC almost always resided in the p53 abn group (positive predictive value: 96%), but it was insensitive as a marker of p53 abn (sensitivity 64%) and the reproducibility of diagnosing SC was suboptimal. The limitations in the precise histologic classification of endometrial carcinomas highlights the importance of an ancillary molecular-based classification scheme.
Comment in
-
Discordance in Pathologist Assessment of Endometrial Cancer is Informative While Level of Discordance of Molecular Classification Remains Unknown.Am J Surg Pathol. 2018 Feb;42(2):277-278. doi: 10.1097/PAS.0000000000000904. Am J Surg Pathol. 2018. PMID: 29176512 No abstract available.
Similar articles
-
Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.Cancer. 2017 Mar 1;123(5):802-813. doi: 10.1002/cncr.30496. Epub 2017 Jan 6. Cancer. 2017. PMID: 28061006
-
[Clinical application of TCGA molecular classification in endometrial endometrioid carcinoma].Zhonghua Bing Li Xue Za Zhi. 2019 Aug 8;48(8):596-603. doi: 10.3760/cma.j.issn.0529-5807.2019.08.003. Zhonghua Bing Li Xue Za Zhi. 2019. PMID: 31422589 Chinese.
-
Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.Gynecol Oncol. 2020 Apr;157(1):245-251. doi: 10.1016/j.ygyno.2020.01.019. Epub 2020 Jan 21. Gynecol Oncol. 2020. PMID: 31980219
-
Molecular Genetics of Endometrial Carcinoma.Annu Rev Pathol. 2019 Jan 24;14:339-367. doi: 10.1146/annurev-pathol-020117-043609. Epub 2018 Oct 17. Annu Rev Pathol. 2019. PMID: 30332563 Review.
-
Reclassifying endometrial carcinomas with a combined morphological and molecular approach.Curr Opin Oncol. 2019 Sep;31(5):411-419. doi: 10.1097/CCO.0000000000000560. Curr Opin Oncol. 2019. PMID: 31261170 Review.
Cited by
-
A new strategy in molecular typing: the accuracy of an NGS panel for the molecular classification of endometrial cancers.Ann Transl Med. 2022 Aug;10(16):870. doi: 10.21037/atm-22-3446. Ann Transl Med. 2022. PMID: 36111057 Free PMC article.
-
Prognostic impact of histological review of high-grade endometrial carcinomas in a large Danish cohort.Virchows Arch. 2021 Sep;479(3):507-514. doi: 10.1007/s00428-021-03133-2. Epub 2021 Jun 11. Virchows Arch. 2021. PMID: 34117532
-
Expression and clinical significance of KLK5-8 in endometrial cancer.Am J Transl Res. 2019 Jul 15;11(7):4180-4191. eCollection 2019. Am J Transl Res. 2019. PMID: 31396327 Free PMC article.
-
Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia.J Gynecol Oncol. 2024 May;35(3):e27. doi: 10.3802/jgo.2024.35.e27. Epub 2023 Dec 18. J Gynecol Oncol. 2024. PMID: 38216133 Free PMC article.
-
Clinicopathologic and Genomic Analysis of TP53-Mutated Endometrial Carcinomas.Clin Cancer Res. 2021 May 1;27(9):2613-2623. doi: 10.1158/1078-0432.CCR-20-4436. Epub 2021 Feb 18. Clin Cancer Res. 2021. PMID: 33602681 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous